TNXP · Tonix Pharmaceuticals Holding Corp.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Feb 5, 2025; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 10, 2026TL;DR. Tonix reported Q2 2026 Tonmaya net sales of approximately $11 million (up 197% QoQ) with expanded payer coverage reaching about 136 million lives, while advancing its TNX-102 SL MDD Phase 2 (first patient enrolled) and keeping the TNX-4800 Lyme Phase 2 on track for Q1 2027 start. Cash of $176.2 million plus subsequent equity proceeds funds operations only into early Q2 2027, and SG&A/R&D roughly doubled YoY as the company ramps the launch and pipeline.
- + Tonmaya Q2 net sales ~$11M, up 197% QoQ (nearly tripled)
- + Strong launch KPIs: 12,592 total Rx (+100%), new patients +36%, refills +207% QoQ
- + Tonmaya coverage expanded to ~136M lives (~43% of U.S.) with GPO deals covering ~52M lives and a managed Medicare deal adding ~9M lives on Jan 1, 2027
- + TNX-4800 Lyme prevention Phase 2 adaptive field study on track to start Q1 2027 after positive FDA Type C minutes
- − Cash runway only into early Q2 2027, with cash declining from ~$207.6M to ~$176.2M
- − R&D expense roughly doubled YoY to ~$19.4M
- − SG&A expense roughly doubled YoY to ~$36.0M as launch costs ramp
- − Net loss widened to ~$40.6M (~$2.44/share) from ~$28.3M YoY
- − Gross-to-net for Tonmaya expected to continue fluctuating in Q3/Q4
- − TNX-4800 Phase 2 enrollment could extend into 2029 if Lyme attack rate is lower than planned
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TNXP
this stock
Tonix Pharmaceuticals Holding Corp.
|
$207.10M | -24.0% | +29.8% | — | 18.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.40B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.67B | +1.2% | +20.8% | 19.6 | 2.5% |
|
ARGX
Argenx SE
|
$61.60B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Feb 5, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TNXP | -11.2% | -5.0% | -20.9% | -15.8% | -24.0% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -10.1% | -3.3% | -38.7% | -15.5% | -36.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.